A phase II trial for advanced epithelioid sarcoma resulted in 15% of patients showing objective responses to treatment.212 As a result, it was approved by the FDA in January 2020 for the treatment of advanced epithelioid sarcoma213 and in June 2020 for the treatment of follicular lymphoma.214Tazemetostat is also currently being evaluated in a phase II trial for paediatric patients with relapsed or refractory tumours with EZH2, SMARCB1 or SMARCA4 mutations (NCT03213665, expected completion September 2024). This evidence concerns the gene SMARCB1 and neoplasm.